IPO Databook: Onconetix (ONCO US) - Aug 2026

91 Views14 Aug 2026 10:08

SUMMARY

Onconetix, Inc. is a commercial stage biotechnology company focused on oncology solutions, primarily its Proclarix in vitro diagnostic test. This filing registers shares for resale by selling stockholders.
Proclarix is CE-marked and for sale in Europe, with a PRIME study initiated in the U.S. market. The company secured $30,249,600 in July 2026 Series F financing.
Cash was approximately $5.4 million as of August 10, 2026. The company has substantial doubt about its ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream